Chairman of new Novozymes company: We might need funding

Chairman of the Board in Novozymes’ biopharma spin-off Albumedix was hired on the strength of his record with spinning out biotech companies. He spoke to MedWatch about proprietary development and the possible need for financing of the new company, which could bring about a change in ownership.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MedWatch-indeks: Endnu en tung uge for biotekaktierne

Nedturen ser ud til at fortsætte for de danske biotekaktier, som alle oplevede kursfald i uge 47. Novo Nordisk ender for en efterhånden sjælden gangs skyld på toppen i MedWatch-indekset, efter at have givet markedet tiltro til fremtiden på sin kapitalmarkedsdag.

Latest Top picks in English

Related articles